Trinity Biotech plc

NASDAQ:TRIB

Medical - Diagnostics & Research

Healthcare
$5.83 -5.73%

-$0.51 today

Market cap
$117.96M
Beta
1.00
P/E (TTM)
-0.1
EPS (TTM)
-$60.27
52W Low $8.00High $103.20

Volume 0.00M

Average 1.34M

TRIB EBITDA

Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.

Trinity Biotech plcNASDAQ: TRIB

EBITDA · Q4 FY2025 · quarter ended Dec 2025

EBITDA remains negative

Q4 FY2025 EBITDA was -$2.21M, compared with -$9.6M a year earlier. Trailing-twelve-month EBITDA was -$8.57M.

Context

  • EBITDA amounted to 48.8% of revenue in FY2025, up 21.4 pp from a year earlier.
  • EBITDA grew in size in 2 of the last 3 fiscal years.

What to watch

Whether EBITDA reaches the consensus estimate from 1 analysts of -$5.91M (+72.3%) for the fiscal year ending Dec 2026, a step up from the -26.5% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterDec 2025
-$2.21M-1938.4% QoQ
Last fiscal yearDec 2025
-$21.38M-26.5% YoY
LTMDec 2025
-$8.57M+49.3% YoY
EBITDA past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+76.9%+132.6%+55.6 pp
1 year-26.5%+72.3%+98.8 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA history

USD · from the income statement

Latest · FY2025
(21.38M) USD
Year-over-year change
-26.5%
Reported Analyst consensus estimate

EBITDA vs competitors

How TRIB compares with its peers on the latest reported figures

No competitor EBITDA figures are available to compare.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue81.15M62.52M56.83M61.56M43.79M
Cost of Revenue54.89M52.73M37.38M40.11M26.9M
Gross Profit33.45M22.05M19.45M21.44M16.89M
Gross Margin41.2%35.3%34.2%34.8%38.6%
Research & Development4.5M4.14M4.38M4.54M3.63M
Selling, General & Admin24.68M29.17M31.15M28.82M24.67M
Operating Expenses29.52M32.96M46.5M42.61M28.3M
Depreciation & Amortization2.74M2.33M1.78M1.87M2.68M
EBITDA10.59M(16.71M)(24.1M)(16.91M)(21.38M)
EBITDA Margin13.1%-26.7%-42.4%-27.5%-48.8%
Operating Income3.94M(15.27M)(27.05M)(21.17M)(11.42M)
Operating Margin4.9%-24.4%-47.6%-34.4%-26.1%
Interest Income1.22M303K1.17M0221K
Interest Expense7.1M24.73M10.15M9.57M13.11M
Other Income / Expenses(5.86M)(24.43M)(9.88M)(9.57M)(25.76M)
Income Before Tax(1.92M)(43.78M)(36.93M)(30.73M)(37.18M)
Pre-Tax Margin-2.4%-70.0%-65.0%-49.9%-84.9%
Income Tax Expense(74K)(194K)(59K)486K199K
Net Income875K(41M)(24.02M)(31.79M)(37.38M)
Net Margin1.1%-65.6%-42.3%-51.6%-85.4%
EPS (Basic)6.30(180.00)(96.00)(52.98)(60.00)
EPS (Diluted)4.92(156.00)(96.00)(52.98)(60.00)
Weighted Avg Shares139.34K224.9K255.17K598.65K619.19K
Weighted Avg Shares (Diluted)177.53K259.16K255.17K598.65K619.19K

Trinity Biotech plc

NASDAQ:TRIB

Intrinsic Alpha fair value

Locked

Current Price

$5.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.